This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Campus
  1. Article
  2. Source: Campus Sanofi
  3. 23 Oct 2023

A cardiologist's view - Professor Azfar Zaman

Author: Sanofi

Editorial Team

                 
Praluent logo

Residual risk in the ACS patient and the contribution of cholesterol
Post-ACS patients may still be at high risk events despite current statin therapy1. Why is it important to do something differently?

Why use Praluent® in patients with ACS?
Odyssey Outcomes data demonstrates the benefit of further LDL-C lowering in the post-ACS population2. Why are these results relevant to cardiologists?

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team

MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References
  1. Jernberg T, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective European Heart Journal (2015) 36, 1163–1170
  2. Schwartz GG, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018; 379: 2097-2107.

MAT-XU-2204596 (v3.0) Date of Preparation: October 2023